CELU

Celularity Inc. (CELU) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Celularity Inc. is a regenerative and cellular medicines company focused on aging-related diseases, operating through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company has no approved cellular therapeutic candidates and relies on revenues from biomaterials and biobanking services to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total net revenues decreased 52.6% in Q2 2025 compared to Q2 2024, driven primarily by a 76.1% drop in product sales (Biovance 3L) partially offset by a 139.3% increase in license, royalty, and other revenue (Rebound sales and CDMO services).
• Increased Losses: Net loss widened significantly to $24.5 million in Q2 2025 from $6.5 million in Q2 2024. This was exacerbated by a $1.3 million loss on the change in fair value of warrant liabilities and a $1.1 million loss on the change in fair value of debt.
• Cost of Revenues: Cost of revenues increased 147% in Q2 2025, largely due to a $1.8 million write-off of capitalized bulk material costs and a $1.2 million milestone accrual for the Rebound asset acquisition.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 20.6% year-over-year due to reduced sales representative fees, while R&D expenses decreased 11.8% due to lower personnel costs.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has insufficient unrestricted cash to fund operations for the next 12 months and requires additional capital to meet obligations.
• Nasdaq Delisting Risk: The company received notice from Nasdaq regarding failure to timely file its 10-Q. While an exception was granted to file by August 31, 2025, failure to comply could result in delisting, which would materially impact the company's ability to raise capital.
• Debt Forbearance: Approximately $6.3 million of current debt is subject to forbearance agreements with lenders (including Yorkville, RWI, and C.V. Starr). Failure to meet terms could lead to asset seizure or liquidation.
• Unusual Items:
  • Recognized a $5.7 million loss on debt extinguishment in the first half of 2025 related to modifications of bridge loans.
  • Recorded a $1.8 million write-off of inventory costs and $1.2 million in milestone payments for the Rebound acquisition.
• Subsequent Events: Post-period, the company entered into a $33.8 million asset purchase agreement with Celeniv Pte. Ltd. to sell intellectual property, with proceeds intended to repay significant bridge loans. Additionally, a $2.0 million private placement was completed in July 2025.

Investor Verification Checklist

• Liquidity Runway: Verify the status of the August 31, 2025, filing deadline with Nasdaq and the progress of the $33.8 million asset sale to Celeniv to determine if immediate delisting or default risks are mitigated.
• Debt Covenants: Review the specific terms of the forbearance agreements with Yorkville, RWI, and C.V. Starr to understand the conditions required to avoid acceleration of debt.
• Revenue Sustainability: Assess the durability of the Rebound product revenue stream versus the decline in core Biovance 3L sales to evaluate future cash flow generation.
• Legal Contingencies: Monitor the status of the Civil Investigative Demand regarding Medicare/Medicaid claims and ongoing litigation with Evolution Biologyx and TCWGlobal.
• Capital Structure: Analyze the impact of recent warrant modifications and equity issuances on potential future dilution.